
-
Adagene Inc NasdaqGM:ADAG Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Location: Building C14, Xinghu Street, Suzhou Industrial Park, Suzhou, 215123, China | Website: https://www.adagene.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
47.54M
Cash
85.19M
Avg Qtr Burn
-7.425M
Short % of Float
0.44%
Insider Ownership
4.70%
Institutional Own.
34.89%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Neoadjuvant Muzastotug (ADG126) Details Colorectal cancer , Cancer | Phase 2 Data readout | |
Muzastotug (ADG126) + KEYTRUDA® (pembrolizumab) Details Colorectal cancer (Advanced MSS CRC) | Phase 1/2 Data readout | |
ADG116 (CTLA4) Details Solid tumor/s, Cancer | Phase 1/2 Update | |
ADG106 (CD137) Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Breast cancer, ER+/HER2- breast cancer | Failed Discontinued |